Foresight Diagnostics: David Kurtz

Foresight Diagnostics has appointed David Kurtz as chief medical officer and head of research. As one of the company's cofounders, Kurtz led the development of Foresight's PhasED-seq technology for cancer minimal residual disease detection. Previously, he was an assistant professor of medicine at Stanford University. He was one of the earliest investigators to explore the utility of tumor-derived cell-free DNA in lymphomas, with a focus on improving the clinical utility and analytical sensitivity of circulating tumor DNA detection methods. Kurtz plans to continue his clinical practice as a medical oncologists part time.